Cosa aggiungono gli inibitori di SGLT2 in termini di nefro-protezione?
|
|
- Raymond Perkins
- 5 years ago
- Views:
Transcription
1 Cosa aggiungono gli inibitori di SGLT2 in termini di nefro-protezione? Giuseppe Pugliese Dipartimento di Medicina Clinica e Molecolare Università di Roma "La Sapienza
2 Disclosure Il Prof. Giuseppe Pugliese dichiara di aver ricevuto negli ultimi due anni compensi o finanziamenti dalle seguenti Aziende Farmaceutiche e/o Diagnostiche: Partecipazioni a Congressi: Astra-Zeneca, Laboratori Guidotti, Sanofi, Takeda; Relazioni / moderazioni / partecipazioni a board retribuite: Astra-Zeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dome, Mylan, Sigma-Tau, Takeda. Il Prof. Giuseppe Pugliese dichiara altresì il proprio impegno ad astenersi, nell ambito dell evento, dal nominare, in qualsivoglia modo o forma, aziende farmaceutiche e/o denominazione commerciale e di non fare pubblicità di qualsiasi tipo relativamente a specifici prodotti di interesse sanitario (farmaci, strumenti, dispositivi medico-chirurgici, ecc.).
3 Agenda General considerations Treatment with SGLT2 inhibitors and renal outcomes Treatment with SGLT2 inhibitors in CKD patients Placing SGLT2 inhibitors in the therapeutic algorithm Mechanisms of nephroprotection with SGLT2 inhibitors
4 Domanda 1 Cosa aggiungono secondo voi gli SGLT2 inibitori in termini di nefro-protezione nel paziente diabetico? Opzioni di risposta A. offrono la possibilità di combinare la nefro-protezione con il controllo della glicemia B. rappresentano una possibile alternativa ad altri farmaci ad azione nefro-protettiva C. non aggiungono molto rispetto ad altri trattamenti quali i bloccanti del RAS D. possono colmare un vuoto nel nostro armamentario terapeutico
5 Unmet needs in diabetic nephropathy Gregg EW et al. N Engl J Med. 2014;370: p=0.39 p<0.001 p<0.001 * Adjusted for age, sex, and race/ethnicity Afkarian M et al. JAMA. 2016;316:
6 Unmet needs in diabetic nephropathy Kramer H et al. Diabetes Care. 2018;41: Cumulative survival (Ref.) Alb - /egfr (1.53, 1.87) 1.75 Alb + /egfr - (1.61, 1.91) 2.76 Alb - /egfr + (2.51, 3.03) Alb + /egfr + Cumulative survival (Ref.) 1.45 (1.33, 1.58) 1.58 (1.43, 1.75) 2.08 (1.88, 2.30) Years of observation Years of observation Penno G et al. Diabetologia. 2018; Jul 21
7 Mechanism of action of SGLT2 inhibitors glicosuria 600 Glucose flux (mg/ml) threshold filtered splay +20% -40% Tm G reabsorbed 0 splay Plasma glucose (mmol/l) 60 Abdul-Ghani MA & DeFronzo RA. EndocrPract. 2008;14:
8 HbA 1c - and egfr-dependent effect of SGLT2 inhibitors Pooled data from 9 phase III studies FDA Endocrinologic and Metabolic Drugs Advisory Committee: Dapagliflozin BMS
9 SGLTs in the kidney Segment 1 (and 2) proximal tubule SGLT-2 Reabsorption of 90-95% glucose (Na + :glucose = 1:1) Low affinity (Km=~2 mm) high capacity Segment 3 proximal tubule SGLT-1 Reabsorption of 5-10% glucose or 40-60% of remaining glucose (Na + :glucose = 2:1) High affinity (Km=~0.2 mm) low capacity Bakris GL et al. Kidney Int. 2009;75:
10 Renal outcomes with SGLT2 inhibitors: empagliflozin The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes trial (EMPA-REG OUTCOME) - Chronic Kidney Disease (CKD) Incident or worsening of nephropathy Post-hoc renal composite outcome * * doubling of serum creatinine, initiation of renal-replacement therapy, or death from renal disease Wanner C et al. N Engl J Med. 2016;375:
11 Renal outcomes with SGLT2 inhibitors: empagliflozin The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes trial (EMPA-REG OUTCOME) - Chronic Kidney Disease (CKD) Renal outcomes Wanner C et al. N Engl J Med. 2016;375:
12 Renal outcomes with SGLT2 inhibitors: empagliflozin The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes trial (EMPA-REG OUTCOME) - Chronic Kidney Disease (CKD) Change in egfr over 192 weeks Change in egfr from baseline to last measurement during treatment & follow-up Wanner C et al. N Engl J Med. 2016;375:
13 Renal outcomes with SGLT2 inhibitors: empagliflozin The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes trial (EMPA-REG OUTCOME) - Chronic Kidney Disease (CKD) Change in ACR over 192 weeks by albuminuria categories ACR at baseline to last measurement during treatment and follow-up by albuminuria categories Cherney DZI et al. Lancet Diabetes Endocrinol. 2017;5:
14 Renal outcomes with SGLT2 inhibitors: empagliflozin The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes trial (EMPA-REG OUTCOME) - Chronic Kidney Disease (CKD) Improvement in albuminuria status From micro to normoalbuminuria From macro to micro or normoalbuminuria Cherney DZI et al. Lancet Diabetes Endocrinol. 2017;5:
15 Renal outcomes with SGLT2 inhibitors: empagliflozin The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes trial (EMPA-REG OUTCOME) - Chronic Kidney Disease (CKD) Change in egfr over 192 weeks by albuminuria categories Cherney DZI et al. Lancet Diabetes Endocrinol. 2017;5:
16 Renal outcomes with SGLT2 inhibitors: canagliflozin The Canagliflozin Cardiovascular Assessment Study (CANVAS) Program CANVAS and CANVAS-Renal (CANVAS-R) Progression of albuminuria* Composite renal outcome * * >30% increase in albuminuria or change from either normo to micro or macroalbuminuria or from micro to macroalbuminuria * 40% reduction in egfr, initiation of renalreplacement therapy, or death from renal disease Neal B et al. N Engl J Med. 2017; Jun 12
17 Renal outcomes with SGLT2 inhibitors: canagliflozin The Canagliflozin Cardiovascular Assessment Study (CANVAS) Program CANVAS and CANVAS-Renal (CANVAS-R) Composite renal outcome * * Doubling of serum creatinine, ESRD, or death from renal disease Perkovic V et al. Lancet Diabetes Endocrinol. 2018;6:
18 Renal outcomes with SGLT2 inhibitors: canagliflozin The Canagliflozin Cardiovascular Assessment Study (CANVAS) Program CANVAS and CANVAS-Renal (CANVAS-R) Renal outcomes Perkovic V et al. Lancet Diabetes Endocrinol. 2018;6:
19 Renal outcomes with SGLT2 inhibitors: canagliflozin The Canagliflozin Cardiovascular Assessment Study (CANVAS) Program CANVAS and CANVAS-Renal (CANVAS-R) Renal outcomes by subgroups Perkovic V et al. Lancet Diabetes Endocrinol. 2018;6:
20 Renal outcomes with SGLT2 inhibitors: canagliflozin The Canagliflozin Cardiovascular Assessment Study (CANVAS) Program CANVAS and CANVAS-Renal (CANVAS-R) Change in egfr over time Perkovic V et al. Lancet Diabetes Endocrinol. 2018;6:
21 Renal outcomes with SGLT2 inhibitors: canagliflozin The Canagliflozin Cardiovascular Assessment Study (CANVAS) Program CANVAS and CANVAS-Renal (CANVAS-R) Change in ACR over time and by albuminuria categories Perkovic V et al. Lancet Diabetes Endocrinol. 2018;6:
22 Renal outcomes with SGLT2 inhibitors: canagliflozin The Canagliflozin Cardiovascular Assessment Study (CANVAS) Program CANVAS and CANVAS-Renal (CANVAS-R) Improvement in albuminuria status From normo to microalbuminuria From normo or micro to macroalbuminuria Perkovic V et al. Lancet Diabetes Endocrinol. 2018;6:
23 Renal outcomes with SGLT2 inhibitors: canagliflozin The Canagliflozin Cardiovascular Assessment Study (CANVAS) Program CANVAS and CANVAS-Renal (CANVAS-R) ACR egfr Renal outcomes by egfr category Annual change from week 6/13 Canagliflozin Placebo HR (95% CI) All 0.33± ± (1.02, 1.35) 0.59 < ± ± (0.62, 2.09) 45-< ± ± (0.62, 1.48) 60-< ± ± (0.89, 1.29) > ± ± (1.05, 1.88) Interaction P value Renal composite* Patients with an event per 1000 patient-years Loss Preservation Canagliflozin Placebo HR (95% CI) All (0.47, 0.77) 0.59 < (0.29, 1.48) 45-< (0.46, 1.31) 60-< (0.41, 0.84) > (0.25, 0.78) Interaction P value * 40% egfr reduction, ESRD, or death from renal disease Favors canagliflozin Favors placebo Neuen B et al. Circulation Jun 25
24 Maintenance of BP (and weight)-lowering effect in CKD patients Canagliflozin Cherney DZI et al. Kidney Int. 2018;93: Petrykiv S et al. Clin J Am Soc Nephrol. 2017;12: Neuen B et al. Circulation Jun 25
25 Mechanisms for maintenance of BP-lowering effect in CKD patients Chan CW & Tang SCW. Kidney Int. 2018;93:22 24
26 A. infezioni urinarie B. chetoacidosi C. acute kidney injury D. fratture Domanda 2 Qual è secondo voi il principale evento avverso che può compromettere l efficacia nefro-protettiva degli SGLT2 inibitori? Opzioni di risposta
27 Mechanisms for AKI under SGLT2 inhibition Hahn K et al. Nat Rev Nephrol. 2016;12:
28 Safety issues with SGLT2 inhibitors: empagliflozin The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes trial (EMPA-REG OUTCOME) - Chronic Kidney Disease (CKD) Wanner C et al. N Engl J Med. 2016;375:
29 Safety issues with SGLT2 inhibitors: canagliflozin The Canagliflozin Cardiovascular Assessment Study (CANVAS) Program CANVAS and CANVAS-Renal (CANVAS-R) Neal B et al. N Engl J Med. 2017;377:
30 Meta-analysis of RCTs AKI with SGLT2 inhibitors Meta-analysis of RCTs Mount Sinai CKD registry and Geisinger Health System cohort Event N AKI OR (95% CI) 0.80 ( ) P Tang H et al. Diabetes Obes Metab. 2017;19: Zhang XL et al. J Am Heart Assoc. 2018;7:e FDA adverse event report system database Nadkarni GN et al. Diabetes Care. 2017;40: Perlman A et al. Nutr Metab Cardiovasc Dis. 2017;27:
31 Therapeutic algorithm for type 2 diabetes CKD? ADA. Standard of Medical Care in Diabetes, 2018
32 Domanda 3 Quali studi ulteriori sono secondo voi necessari per legittimare l uso degli SGLT2 inibitori per la nefroprotezione nel paziente diabetico? Opzioni di risposta A. studi di confronto con farmaci ad azione nefroprotettiva B. studi di efficacia in cui l outcome renale sia l endpoint primario C. studi di sicurezza in pazienti con ridotta funzione renale D. studi di efficacia in prevenzione primaria
33 Ongoing trials with primary renal endpoints The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Primary endpoint: composite of ESRD, doubling of serum creatinine, and renal or CV death. Anticipated targets: 4,401 randomized Event-driven Duration 5.5 years Secondary endpoints: Renal composite of ESRD, doubling of serum creatinine, and renal death; HF composite of CV death and hospitalization for congestive heart failure; CV composite of CV death, nonfatal acute myocardial infarction or stroke hospitalization for congestive heart failure or unstable angina; CV death; All-cause death. Clinicaltrials.gov.
34 Ongoing trials with primary renal endpoints A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (Dapa-CKD) Population: Diabetic and nondiabetic pts. CKD stage 2-4 UACR >200 mg/g Dapagliflozin 10 mg Placebo Primary endpoint: composite of ESRD, 50% egfr decline, and renal or CV death. Secondary endpoints: Renal composite of ESRD, 50% egfr decline, and renal death; HF composite of CV death and hospitalization for congestive heart failure; All-cause death. Anticipated targets: 4,000 randomized Event-driven Duration 45 months Clinicaltrials.gov.
35 Mechanisms of renal protection with SGLT2 inhibitors 2 glucotoxicity 1 glomerular hyperfiltration 4 NHE3 6 HIF 3 H 2O, Na +, and uric acid excretion 5 ketonemia Vallon V & Thomson SC. Diabetologia. 2017;60:
36 Glomerular hyperfiltration in diabetes C SN SN SN Surviving nephrons reduced GFR SN X Lost nephrons Hyperfiltration in residual nephrons in late stages of diabetic nephropathy Cherney D et al. Circulation. 2014;129:
37 Reduction of glomerular hyperfiltration with SGLT2 inhibitors Cherney D et al. Circulation. 2014;129:
38 Reduction of glomerular hyperfiltration with SGLT2 inhibitors SNGPF P glom Vallon V & Thomson SC. Diabetologia. 2017;60: Heerspink IJL et al. Diabetes Obes Metab. 2013;15:
39 Complementary actions of SGLT2 inhibitors and RAS blockers Perkovic V et al. Curr Med Res Opin. 2015;12:
40 Na + reabsorption in the kidney GFR, AT-II, Norepinephrine Proximal convoluted tubule (55-65%) Na + co-transporters Na + /H + exchangers Flow-dependent Distal convoluted tubule (5-7%) Na + /Cl - co-transporters Thiazide diuretics SGLT2 inhibitors Carbonic anhydrase inhibitors Flow-dependent Thick ascending limb of the loop of Henle (25-35%) Na + /K + /2Cl - co-transporters Loop diuretics Urine 1% Aldosterone, ANP Collecting duct (2-4%) Na + channels Amiloride, triamterene, Aldosterone receptor blockers
41 Sustained increase in urinary glucose excretion with SGLT2 inhibitors Bolinder J et al. Diabetes Obes Metab. 2014;16:
42 Sustained reduction in plasma volume with SGLT2 inhibitors Heerspink IJL et al. Diabetes Obes Metab. 2013;15:
43 Increased urate excretion with SGLT2 inhibitors Qiu H et al. Diabetes Metab Res Rev. 2017;33:e2886
44 Loop diuretic sparing effect of SGLT2 inhibitors The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes trial (EMPA-REG OUTCOME) Fitchett D et al. Eur Heart J. 2016;37:
45 Reduced chloride concentration and NKCC inhibition NKCC = Na-K-2Cl co-transporter Greger R et al. Kidney Int. 1987;31:
46 The thrifty substrate Ferrannini E et al. Diabetes Care. 2016; 39:
47 Shift in fuel energetics with SGLT2 inhibitors Mudaliar S et al. Diabetes Care. 2016; 39:
48 Hypoxia-dependent effects of SGLT2 inhibitors O Neill J et al. Am J Physiol Renal Physiol. 2015;309:F227 F234
49 Increased hematocrit with SGLT2 inhibitors Heerspink IJL et al. Diabetes Obes Metab. 2013;15:
50 Conclusions There is an unmet need for effective measures for nephroprotection in diabetic patients. Trials with SGLT2 inhibitors have shown promising effects of these agents on renal outcomes, including decrease of both albuminuria and egfr decline. Treatment with SGLT2 inhibitors in CKD patients is less effective in reducing blood glucose, but not blood pressure levels and appears equally effective in improving cardiovascular and renal outcomes. Safety concerns with respect to nephroprotection include increased risk of AKI, which is mainly related to volume depletion and may be prevented by appropriate management of diuretic therapy. Further studies, including the ongoing trials with primary renal endpoints, are required for recommending SGLT2 inhibitors as nephroprotective agents in diabetic (and non-diabetic) individuals. Multiple mechanisms seems to be involved in nephroprotection with SGLT2 inhibitors, including reduced glomerular hyperfiltration and glucose-toxicity, volume depletion, urate excretion, shift in fuel energetics, and hypoxia-dependent effects.
Update sul danno macrovascolare: fisiopatologia e indicazioni per la prevenzione
Update sul danno macrovascolare: fisiopatologia e indicazioni per la prevenzione Marco Giorgio Baroni Department of Experimental Medicine Sapienza University of Rome, Italy Il sottoscritto Marco Giorgio
More informationSGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection
SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center
More information- Johnson & Johnson - Roche S.p.a. - Healthware per Sanofi
Il dr. Pintaudi Basilio dichiara di aver ricevuto negli ultimi due anni compensi o finanziamenti dalle seguenti Aziende Farmaceutiche e/o Diagnostiche: - Johnson & Johnson - Roche S.p.a. - Healthware per
More informationEmanuele Bosi dichiara di aver ricevuto negli ultimi due anni compensi o finanziamenti dalle seguenti Aziende Farmaceutiche e/o Diagnostiche:
Emanuele Bosi dichiara di aver ricevuto negli ultimi due anni compensi o finanziamenti dalle seguenti Aziende Farmaceutiche e/o Diagnostiche: - Abbott - Roche - Takeda - Novartis - Astra Zeneca - Medtronic
More informationIl Dr. Giampaolo Niccoli dichiara di non aver ricevuto negli ultimi due anni compensi o finanziamenti da Aziende Farmaceutiche e/o Diagnostiche:
Il Dr. Giampaolo Niccoli dichiara di non aver ricevuto negli ultimi due anni compensi o finanziamenti da Aziende Farmaceutiche e/o Diagnostiche: Dichiara altresì il proprio impegno ad astenersi, nell ambito
More informationGli endpoint micro-vascolari nei trial di outcome cardiovascolare
Gli endpoint micro-vascolari nei trial di outcome cardiovascolare Giorgio Sesti University Magna Graecia of Catanzaro ITALY Potenziali conflitti di interesse Il Prof Giorgio Sesti dichiara di aver ricevuto
More informationLa protezione cardiovascolare degli inibitori di SGLT2: trial e studi osservazionali
La protezione cardiovascolare degli inibitori di SGLT2: trial e studi osservazionali Saula Vigili de Kreutzenberg Studi di Padova Università degli Il /la dr./sa Saula Vigili de Kreutzenberg dichiara di
More informationPaolo Fornengo SCDU Medicina Interna 3 AOU Città della Salute e della Scienza di Torino
Paolo Fornengo SCDU Medicina Interna 3 AOU Città della Salute e della Scienza di Torino The KID-ney behind the curtain Altered Renal Glucose Control in Diabetes Gluconeogenesis is increased in postprandial
More informationCONGRESSO REGIONALE AMD - SID. Alleanza strategica nella gestione del paziente diabetico: attori a confronto Roma, 5-6 maggio 2017
CONGRESSO REGIONALE AMD - SID Alleanza strategica nella gestione del paziente diabetico: attori a confronto Roma, 5-6 maggio 2017 Il /la dr./sa Martina Vitale dichiara di NON aver ricevuto negli ultimi
More informationManaging patients with renal disease
Managing patients with renal disease Hiddo Lambers Heerspink, MD University Medical Centre Groningen, The Netherlands Asian Cardio Diabetes Forum April 23 24, 216 Kuala Lumpur, Malaysia Prevalent cases,
More informationPROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI. Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona
PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona Disclosure Dr Massimo Boemi has been granted as speaker
More informationLa lezione dei trials di safety cardiovascolare. Edoardo Mannucci
La lezione dei trials di safety cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer
More informationEffect of SGLT-2 Inhibitors on the Heart. Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic
Effect of SGLT-2 Inhibitors on the Heart Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic Disclosures Speaker - Johnson and Johnson - Merck Research - Merck - Novo
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationSGLT2-inhibition: A New Strategy to Protect the Heart and the Kidney?
SGLT2-inhibition: A New Strategy to Protect the Heart and the Kidney? Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center Groningen The Netherlands Disclosures:
More informationSodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes
Editorial Page 1 of 5 Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes Hidekatsu Yanai Department of Internal Medicine, National Center for Global Health and Medicine
More informationIl razionale delle associazioni terapeutiche sulla protezione cardiovascolare
Il razionale delle associazioni terapeutiche sulla protezione cardiovascolare Alessandra Dei Cas UOC di Endocrinologia e Malattie del Metabolismo Dipartimento di Medicina e Chirurgia Università di Parma
More informationThe Role Of SGLT-2 Inhibitors In Clinical Practice. Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs
The Role Of SGLT-2 Inhibitors In Clinical Practice Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs Disclosure of Potential Conflicts of Interest Consultantship
More informationDu gusts is megl che one. Edoardo Mannucci
Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationGli inibitori di SGLT-2 possono essere impiegati nel diabete di tipo 1?
Impatto degli inibitori di SGLT-2 nei pazienti con diabete di tipo 2 Corso SID Hotel Michelangelo, Milano. 26 Giugno 2018 Gli inibitori di SGLT-2 possono essere impiegati nel diabete di tipo 1? Emanuele
More informationTerapia con agonisti GLP1 e outcome cardiovascolare. Edoardo Mannucci
Terapia con agonisti GLP e outcome cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca,
More informationIl blocco del cotrasportatore. della terapia antiiperglicemica. Anna Solini
Il blocco del cotrasportatore sodioglucosio come target della terapia antiiperglicemica Anna Solini Dipartimento di Patologia Chirurgica, Medica, Molecolare e dell Area Critica Università di Pisa Grant
More informationChapter 21. Diuretic Agents. Mosby items and derived items 2008, 2002 by Mosby, Inc., an affiliate of Elsevier Inc.
Chapter 21 Diuretic Agents Renal Structure and Function Kidneys at level of umbilicus Each weighs 160 to 175 g and is 10 to 12 cm long Most blood flow per gram of weight in body 22% of cardiac output (CO)
More informationCARDIO-RENAL SYNDROME
CARDIO-RENAL SYNDROME Luis M Ruilope Athens, October 216 DISCLOSURES: ADVISOR/SPEAKER for Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Esteve, GSK Janssen, Lacer, Medtronic, MSD, Novartis, Pfizer, Relypsa,
More informationVariability in drug response: towards more personalized diabetes care Petrykiv, Sergei
University of Groningen Variability in drug response: towards more personalized diabetes care Petrykiv, Sergei IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you
More informationPreventing Serious Health Consequences of Type 2 Diabetes
Preventing Serious Health Consequences of Type 2 Diabetes The Evidence Hertzel C. Gerstein MD MSc FRCPC Professor and Population Health Institute Chair in Diabetes Research McMaster University and Hamilton
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationThe EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada
The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationFarmaci innovativi e terapie di associazione: quali opportunità? Giuseppe Penno Dipartimento di Medicina Clinica e Sperimentale
Farmaci innovativi e terapie di associazione: quali opportunità? Giuseppe Penno Dipartimento di Medicina Clinica e Sperimentale Dichiarazione esplicita di trasparenza delle fonti di finanziamento e dei
More informationNuove opportunità terapeutiche nel Diabete Mellito
Nuove opportunità terapeutiche nel Diabete Mellito Raffaele Napoli UOSD Medicina Interna ad indirizzo Diabetologico Dipartimento di Scienze Mediche Traslazionali, Università Federico II di Napoli 1 Potenziali
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationHot Topics in Diabetic Kidney Disease a primary care perspective
Hot Topics in Diabetic Kidney Disease a primary care perspective DR SARAH DAVIES GP PARTNER WITH SPECIAL INTEREST IN DIABETES, CARDIFF DUK CLINICAL CHAMPION NB MEDICAL HOT TOPICS PRESENTER AND DIABETES
More informationSGLT-2 INHIBITORS: CVD REDUCTION THROUGH DIURESIS
SGLT-2 INHIBITORS: CVD REDUCTION THROUGH DIURESIS Dr. Kirtida Acharya National chair, Diabetes Kenya Consultant Endocrinologist/Diabetologist, MP Shah Hospital KCS Symposium, 30 th June, 2017 Sarova Whitesands,
More informationCan Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure?
UCSD Hawaii 2017 Symposium Can Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure? Gregg C. Fonarow, MD, FACC, FAHA Elliot Corday Professor of Cardiovascular Medicine UCLA Division of Cardiology
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationManagement of New-Onset Proteinuria in the Ambulatory Care Setting. Akinlolu Ojo, MD, PhD, MBA
Management of New-Onset Proteinuria in the Ambulatory Care Setting Akinlolu Ojo, MD, PhD, MBA Urine dipstick results Negative Trace between 15 and 30 mg/dl 1+ between 30 and 100 mg/dl 2+ between 100 and
More informationRENAL SYSTEM 2 TRANSPORT PROPERTIES OF NEPHRON SEGMENTS Emma Jakoi, Ph.D.
RENAL SYSTEM 2 TRANSPORT PROPERTIES OF NEPHRON SEGMENTS Emma Jakoi, Ph.D. Learning Objectives 1. Identify the region of the renal tubule in which reabsorption and secretion occur. 2. Describe the cellular
More informationThe albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients
Received: 5 February 217 Revised: 1 March 217 Accepted: 8 March 217 DOI: 1.1111/dom.12936 ORIGINAL ARTICLE The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual
More informationSESSION 4 12:30pm 1:45pm
SESSION 4 12:30pm 1:45pm Addressing Renal-Mediated Glucose Homeostasis: Diabetes and the Kidney SPEAKER Davida Kruger, MSN, BC-ADM, APRN Presenter Disclosure Information The following relationships exist
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationDiscussant Primary and Secondary Prevention of CV Events in the CANVAS Program
Discussant Primary and Secondary Prevention of CV Events in the CANVAS Program M. Angelyn Bethel, MD Associate Professor of Diabetes and Endocrinology University of Oxford UK Aims & major findings Aims:
More informationQuando l insulina basale non basta più: differenti e nuove strategie terapeutiche
Quando l insulina basale non basta più: differenti e nuove strategie terapeutiche Giorgio Sesti Università Magna Graecia di Catanzaro Potenziali conflitti di interesse Il Prof Giorgio Sesti dichiara di
More informationDiabetes and kidney disease.
Diabetes and kidney disease. What are the implications? Can it be prevented? Nice 18 june 2010 Lars G Weiss. M.D. Ph.D. Department of Neprology Central Hospital Karlstad Sweden Diabetic nephropathy vs
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationEndocrinologist Sweetgrass Endocrinology
Endocrinologist Sweetgrass Endocrinology Sanders, Cummings Ask Justice Department to Investigate Insulin Prices The Department of Justice and the FTC are asked to investigate whether Lilly, Novo Nordisk,
More informationSGLT2 Inhibitors: Town Hall Benefits vs Concerns: A renal perspective
SGLT2 Inhibitors: Town Hall Benefits vs Concerns: A renal perspective Matthew R. Weir, MD Professor and Chief Division of Nephrology University of Maryland School of Medicine Disclosure Slide Scientific
More informationLower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6 10
6 Diabetes Care Volume 41, January 2018 PERSPECTIVES IN CARE Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6 10 https://doi.org/10.2337/dc17-1223
More informationRenal Physiology II Tubular functions
Renal Physiology II Tubular functions LO. 42, 43 Dr. Kékesi Gabriella Basic points of renal physiology 1. Glomerular filtration (GF) a) Ultrafiltration 2. Tubular functions active and passive a) Reabsorption
More informationDapagliflozin and cardiovascular outcomes in type 2
EARN 3 FREE CPD POINTS diabetes Leader in digital CPD for Southern African healthcare professionals Dapagliflozin and cardiovascular outcomes in type 2 diabetes Introduction People with type 2 diabetes
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationNew Trials. Iain Squire. Professor of Cardiovascular Medicine University of Leicester. Chair, BSH
New Trials Iain Squire Professor of Cardiovascular Medicine University of Leicester Chair, BSH BSH Heart Failure Day for Revalidation and Training 2017 Presentation title: New Trials Speaker: Iain Squire
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationDIURETICS-2. Dr. Shariq Syed. Shariq AIKC/TYB/2014
DIURETICS-2 Dr. Syed Structure of Kidney Blood filtered by functional unit: Nephron Except for cells, proteins, other large molecules, rest gets filtered Structure of Kidney 3 major regions of nephron
More informationNuove e Vecchie Diete per il Paziente con Diabete
Nuove e Vecchie Diete per il Paziente con Diabete Prof. Angela A. Rivellese Dipartimento di Medicina Clinica e Chirurgia Università degli Studi di Napoli Federico II Dichiaro di aver ricevuto negli ultimi
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationFirenze 22 settembre 2007
Istituto di di medicina dello sport di di Firenze AMES Prevenzione cardiovascolare e cambiamenti negli stili di vita Firenze 22 settembre 2007 Orientamenti attuali per un intervento farmacologico e non
More informationImpatto dei farmaci antidiabetici sullo scompenso cardiaco
Impatto dei farmaci antidiabetici sullo scompenso cardiaco Riccardo Candido S.S.D. Gestione Rete Diabetologica Aziendale Azienda Sanitaria Universitaria Integrata di Triste Il sottoscritto Riccardo Candido
More information23-Jun-15. Albuminuria Renal and Cardiovascular Consequences A history of progress since ,490,000. Kidney Center, UMC Groningen
Kidney function (egfr in ml/min) Albuminuria (mg/hr) Incidentie ESRD (%) 3-Jun- Number of patients worldwide that receives kidney replacement therapy Albuminuria Renal and Cardiovascular Consequences A
More informationRenal Physiology - Lectures
Renal Physiology - Lectures Physiology of Body Fluids PROBLEM SET, RESEARCH ARTICLE Structure & Function of the Kidneys Renal Clearance & Glomerular Filtration PROBLEM SET Regulation of Renal Blood Flow
More informationKidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)
Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension
More informationManaging Chronic Kidney Disease: Reducing Risk for CKD Progression
Managing Chronic Kidney Disease: Reducing Risk for CKD Progression Arasu Gopinath, MD Clinical Nephrologist, Medical Director, Jordan Landing Dialysis Center Objectives: Identify the most important risks
More informationCardiologists and HbA1c: Novel Diabetes Drugs and the Cardiologist as Diabetician
Biomarkers 2019 Cardiologists and HbA1c: Novel Diabetes Drugs and the Cardiologist as Diabetician Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationDM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!
DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! Kevin M. Pantalone, DO, ECNU, CCD Associate Staff Director of Clinical Research Department of Endocrinology Endocrinology and
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationSGLT2 Inhibitors From Discovery to Clinical Practice
SGLT2 Inhibitors From Discovery to Clinical Practice Sunder Mudaliar, MD, FRCP (Edin), FACP, FACE Clinical Professor of Medicine University of California, San Diego Staff Physician VA San Diego Healthcare
More informationMSD NOVO NOVARTIS LILLY
Il Prof. Giuseppe Paolisso dichiara di aver ricevuto negli ultimi due anni compensi o finanziamenti dalle seguenti Aziende Farmaceutiche e/o Diagnostiche: MSD NOVO NOVARTIS LILLY The Role of Inflammation
More informationDespite the irrefutable evidence for the important
PERSPECTIVES IN DIABETES Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30 50% of Filtered Glucose Load in Humans Muhammad A. Abdul-Ghani, Ralph A. DeFronzo, and Luke Norton Inhibitors of
More informationAmbrish Mithal MD, DM
Ambrish Mithal MD, DM Chairman, Division of Endocrinology and Diabetes Medanta The Medicity Padma Bhushan Awardee 2015, Member Governing Council, Indian Council of Medical Research (ICMR) Dr Mithal is
More informationCanagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program Kenneth W. Mahaffey, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Greg Fulcher,
More informationHeart Failure Management in T2 DM A Practical Approach. David Fitchett MD St Michael s Hospital Toronto
Heart Failure Management in T2 DM A Practical Approach David Fitchett MD St Michael s Hospital Toronto Faculty: Faculty Disclosure David Fitchett MD,, FRCP(C) Associate Professor of Medicine, University
More informationCardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials
Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials Rajiv Roy, MD Endocrinology Sharp Rees-Stealy Medical Group Background Between 1990 and 2010: Incidence of
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients
More informationNephron Function and Urine Formation. Ms. Kula December 1, 2014 Biology 30S
Nephron Function and Urine Formation Ms. Kula December 1, 2014 Biology 30S The Role of the Nephron In order for the body to properly function and maintain homeostasis, the amount of dissolved substances
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationAggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
http://www.kidney-international.org & 2013 International Society of Nephrology Aggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
More informationDiuretic Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Diuretic Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Potassium-sparing diuretics The Ion transport pathways across the luminal and basolateral
More informationKidney Disease, Hypertension and Cardiovascular Risk
1 Kidney Disease, Hypertension and Cardiovascular Risk George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Unit The University of Chicago-Pritzker School of Medicine Chicago,
More informationEmpagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Diabetes Ther (2017) 8:33 53 DOI 10.1007/s13300-016-0211-x REVIEW Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus John E. Anderson. Eugene E. Wright Jr.. Charles F.
More informationNew Strategies for Cardiovascular Risk reduction in Diabetes
New Strategies for Cardiovascular Risk reduction in Diabetes Dr. Godwin LEUNG Tat Chi MB ChB(HK), MRCP (UK), FHKCP, FHKAM (Medicine) FRCP (Glasg), FACC Specialist in Cardiology % event as first CV event
More informationDiabetes and Hypertension
Diabetes and Hypertension William C. Cushman, MD, FAHA, FACP, FASH Chief, Preventive Medicine, Veterans Affairs Medical Center Professor, Preventive Medicine, Medicine, and Physiology University of Tennessee
More informationTreatment of diabetic kidney disease: landmark studies and tribulations
Division of Nephrology, Department of Medicine, The University of Hong Kong Treatment of diabetic kidney disease: landmark studies and tribulations Sydney C.W. TANG APSN/JSN Continuing Medical Education
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationLa nefropatia diabetica. Inquadramento diagnostico della nefropatia diabetica
La nefropatia diabetica Inquadramento diagnostico della nefropatia diabetica Giuseppe Penno Dipartimento di Medicina Clinica e Sperimentale Università di Pisa Dichiarazione esplicita di trasparenza delle
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationSPRINT: Consequences for CKD patients
SPRINT: Consequences for CKD patients 29 e Workshop Nierziekten Papendal 2018 December 12, 2018 MICHAEL ROCCO, MD, MSCE VARDAMAN M. BUCKALEW JR. PROFESSOR OF MEDICINE PROFESSOR OF PUBLIC HEALTH SCIENCES
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More informationNa + Transport 1 and 2 Linda Costanzo, Ph.D.
Na + Transport 1 and 2 Linda Costanzo, Ph.D. OBJECTIVES: After studying this lecture, the student should understand: 1. The terminology applied to single nephron function, including the meaning of TF/P
More information